ClinicalTrials.gg
RecruitingNCT07616921Updated Oct 29, 2026

A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

An interventional study of Aerobic Exercise and Resistance Training in Acute Myeloid Leukemia, sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Washington · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Leukemia, Myeloid, Acute by University of Washington — 5 open to participants now, 5 under way, none of them phase 3. Leukemia, Myeloid, Acute · University of Washington.

Planned enrollment
8th of 15
30 · median 30
Started
2026
the only one that year
No phase
6 of 15
2 open now
Registered
15th of 15
by date

Among the 15 studies in Leukemia, Myeloid, Acute by University of Washington, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 6 with no phase, and was the 15th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

5 of the 15 studies in Leukemia, Myeloid, Acute by University of Washington are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Leukemia, Myeloid, Acute by University of Washington, or all of them as a file.
02

Study summary

This clinical trial studies how well a home-based exercise intervention called Cardiorespiratory Fitness in Bone Marrow Transplant Program (CAREFit-BMT) works in improving heart function among patients with high risk acute myeloid leukemia (AML) undergoing stem cell transplant. Older adults and those with other medical conditions are at a higher risk for complications in the heart and blood vessels (cardiovascular). Older age at transplantation has been associated with nearly all cardiovascular complications occurring after stem cell transplant. This is likely explained by the structural and functional changes that occur in aging hearts as well as the larger burden of cardiovascular risk factors such as diabetes, high blood pressure, and obesity. CAREFit-BMT is a "prehabilitation" program, or exercise initiated prior to intensive therapy, that consists of aerobic exercises and strength training. CAREFit-BMT may be able to increase the likelihood of safe and successful transition to stem cell transplant in patients with high risk AML.

Read the detailed description

OUTLINE:

Patients undergo at-home moderate-intensity aerobic exercises over 30 minutes, 5 days per week, as well as strength training over 15-30 minutes, 3 days per week for up to 12 weeks in the absence of unacceptable toxicity. Patients also undergo blood sample collection throughout the study.

After completion of the study intervention, patients are followed for 12 months.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Ability to understand and willingness to sign a written document
  • New diagnosis of acute myeloid leukemia at Fred Hutch
  • High-risk patients as defined by one, or more, of the following criteria:

    • Age 65 years or older and/or
    • Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score ≥ 3 (for patients 20 years old or older) and/or
    • CARE-BMT score ≥ 5

      • Note: HCT-CI and CARE-BMT scores will be measured at pre-screening by study staff
  • Able to exercise at low to moderate intensity, as evaluated by study staff
  • Access to a mobile smart phone
  • Able to read and write in English

Exclusion criteria

Exclusion Criteria:

  • Orthopedic, neurologic, or other problems that prevent safe ambulation and protocol adherence. Information on prior falls and other recent orthopedic or neurologic problems will be used to make judgment about protocol eligibility
  • Recurrence of AML or diagnosis of other invasive cancer
  • Severe anemia ( \< 7 gm/dl)
  • History of severe aortic stenosis
  • (NYHA) class IV heart failure
  • Severe pain with basic movement
  • Pregnant persons
  • Unable to give consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Supportive Care (CAREFit-BMT exercise program)

    Patients undergo at-home moderate-intensity aerobic exercises over 30 minutes, 5 days per week, as well as strength training over 15-30 minutes, 3 days per week for up to 12 weeks in the absence of unacceptable toxicity. Patients also undergo blood sample collection throughout the study.

    Other: Aerobic Exercise · Other: Resistance Training · Procedure: Biospecimen Collection · Other: Electronic Health Record Review · Other: Survey Administration · Other: Interview

Interventions

  • OtherAerobic Exercise

    Undergo moderate-intensity aerobic exercises

    Also known as: Aerobic Activity

  • OtherResistance Training

    Undergo strength training

    Also known as: Strength Training

  • ProcedureBiospecimen Collection

    Undergo collection of blood

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • OtherElectronic Health Record Review

    Ancillary studies

  • OtherSurvey Administration

    Ancillary studies

  • OtherInterview

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Recruitment rates (Feasibility)

    Recruitment will be calculated as the proportion of eligible patients who provide informed consent, with 95% confidence intervals, and reasons for ineligibility or refusal summarized from screening logs.

    Time frame: Up to 24 months

  2. Retention rates (Feasibility)

    Retention will be defined as the proportion of enrolled participants who complete the post-intervention assessment, also with 95% confidence intervals.

    Time frame: Up to 24 months

  3. Adherence to program (Feasibility)

    Adherence will be evaluated from both aerobic and resistance training participation, including the percentage of prescribed sessions completed and average weekly minutes of moderate-intensity aerobic activity from wearable device data.

    Time frame: At the end of the CAREFit-BMT program (Day 85)

  4. Overall satisfaction (Feasibility): Acceptability of Intervention Measure mean score

    Acceptability will be assessed using validated instrument, Acceptability of Intervention Measure, summarized as means with standard deviations. Scores range from 1 to 5, with higher scores indicating greater acceptability.

    Time frame: At the end of the CAREFit-BMT program (Day 85)

  5. Overall satisfaction (Feasibility): Intervention Appropriateness Measure mean score

    Will be assessed using validated instrument, Intervention Appropriateness Measure, summarized as means with standard deviations. Scores range from 1 to 5, with higher scores indicating greater appropriateness.

    Time frame: At the end of the CAREFit-BMT program (Day 85)

  6. Overall satisfaction (Feasibility): Feasibility of Intervention Measure mean score

    Will be assessed using validated instrument, Feasibility of Intervention Measure, summarized as means with standard deviations. Scores range from 1 to 5, with higher scores indicating greater feasibility.

    Time frame: At the end of the CAREFit-BMT program (Day 85)

Secondary outcomes

  1. Barriers and facilitators of Cardiorespiratory Fitness in Bone Marrow Transplant Program (CAREFit-BMT)

    Participant-specific barriers and facilitators to enrollment, participation, and adherence, will be assessed through semi-structured qualitative interviews informed by the Capability, Opportunity, Motivation, and Behavior (COM-B) framework.

    Time frame: At the end of the CAREFit-BMT program (Day 85)

  2. Changes in cardiorespiratory fitness (CRF): Mean change in Anaerobic threshold

    Will be measured by cardiopulmonary exercise testing to assess anaerobic threshold. Within-participant change will be summarized as mean paired differences with two-sided 95% confidence intervals, standard deviations, and standardized mean changes. If distributions are notably non-normal (e.g. biomarkers), non-parametric paired methods will be used.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

  3. Changes in cardiorespiratory fitness (CRF): Mean change in Peak oxygen consumption (VO₂peak)

    Will be measured by cardiopulmonary exercise testing to assess peak oxygen consumption (VO₂peak). Within-participant change will be summarized as mean paired differences with two-sided 95% confidence intervals, standard deviations, and standardized mean changes. If distributions are notably non-normal (e.g. biomarkers), non-parametric paired methods will be used.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

  4. Changes in cardiorespiratory fitness (CRF): Mean change in VO₂peak percent-predicted

    Will be measured by cardiopulmonary exercise testing to assess VO₂peak percent-predicted. Within-participant change will be summarized as mean paired differences with two-sided 95% confidence intervals, standard deviations, and standardized mean changes. If distributions are notably non-normal (e.g. biomarkers), non-parametric paired methods will be used.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

  5. Changes in cardiorespiratory fitness (CRF): Mean change in Respiratory exchange ratio at peak

    Will be measured by cardiopulmonary exercise testing to assess respiratory exchange ratio at peak. Within-participant change will be summarized as mean paired differences with two-sided 95% confidence intervals, standard deviations, and standardized mean changes. If distributions are notably non-normal (e.g. biomarkers), non-parametric paired methods will be used.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

  6. Changes in cardiorespiratory fitness (CRF): Mean change in Minute ventilation/carbon dioxide production (VE/VCO₂) slope

    Will be measured by cardiopulmonary exercise testing to assess minute ventilation/carbon dioxide production (VE/VCO₂) slope. Within-participant change will be summarized as mean paired differences with two-sided 95% confidence intervals, standard deviations, and standardized mean changes. If distributions are notably non-normal (e.g. biomarkers), non-parametric paired methods will be used.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

  7. Changes in cardiovascular (CV) symptoms

    Will be measured using the Kansas City Cardiomyopathy Questionnaire-12. Standardized scores range from 0-100, with higher scores indicating better outcome.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

  8. Changes in CV biomarkers

    Will include cardiac troponins (I \& T), NT-pro-BNP, and IL-6 measured in collected blood samples through University of Washington Research Testing Service.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

  9. Changes in quality of life

    Will be assessed using the Functional Assessment of Cancer Therapy Bone Marrow Transplant questionnaire. Total scores range from 0-148, with higher scores indicating better outcome.

    Time frame: Baseline up to the end of the CAREFit-BMT program (Day 85)

07

Study locations

1 of 1 sites recruiting
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
    Recruiting
    • Alexi Vasbinder, PhD, RN · Contactavasbind@uw.edu · 206-221-4390
    • Alexi Vasbinder, PhD, RN · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 16 months is below that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
Jun 1, 2026
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Apr 3, 2028
CompletionEst.
Apr 3, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Dec 1, 2026
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Oct 15, 2026→Dec 1, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07616921
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Apr 3, 2028 (estimated)
Completion
Apr 3, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Alexi Vasbinder, PhD, RN
Contact
avasbind@uw.edu
206-221-4390
Alexi Vasbinder, PhD, RN
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion